Q2 EPS Estimates for VVOS Cut by Ascendiant Capital Markets

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – Investment analysts at Ascendiant Capital Markets reduced their Q2 2026 earnings estimates for shares of Vivos Therapeutics in a research report issued to clients and investors on Thursday, June 4th. Ascendiant Capital Markets analyst L. Ward now expects that the company will post earnings of ($0.54) per share for the quarter, down from their prior estimate of ($0.39). Ascendiant Capital Markets currently has a “Buy” rating and a $3.10 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.39) per share. Ascendiant Capital Markets also issued estimates for Vivos Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.14) EPS and FY2027 earnings at ($2.17) EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Monday, April 20th. HC Wainwright decreased their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $2.80.

Vivos Therapeutics Stock Performance

Shares of VVOS stock opened at $0.64 on Thursday. The firm’s 50 day moving average price is $0.87 and its 200-day moving average price is $1.46. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.27 and a current ratio of 0.27. Vivos Therapeutics has a one year low of $0.55 and a one year high of $7.95. The firm has a market cap of $8.88 million, a P/E ratio of -0.30 and a beta of 6.10.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.07). Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.The company had revenue of $5.14 million during the quarter, compared to analyst estimates of $4.35 million.

Insider Buying and Selling at Vivos Therapeutics

In other Vivos Therapeutics news, major shareholder Michael C. Skaff acquired 1,353,625 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the acquisition, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VVOS. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the second quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics in the second quarter valued at approximately $220,000. Connective Capital Management LLC acquired a new position in shares of Vivos Therapeutics in the third quarter valued at approximately $620,000. Acorn Wealth Advisors LLC acquired a new position in shares of Vivos Therapeutics in the fourth quarter valued at approximately $30,000. Finally, DRW Securities LLC grew its holdings in shares of Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares in the last quarter. Institutional investors and hedge funds own 26.35% of the company’s stock.

Key Vivos Therapeutics News

Here are the key news stories impacting Vivos Therapeutics this week:

• Positive Sentiment: Vivos announced a collaboration with a multi-location Florida cardiology group to expand sleep apnea and insomnia diagnosis and treatment for cardiovascular patients, which could help widen its referral pipeline and support future growth. Article Title
• Neutral Sentiment: Ascendiant Capital Markets kept a Buy rating and $3.10 price target on VVOS, but it also issued long-term earnings estimates that remain deeply negative, suggesting the stock still depends on a turnaround in profitability. Article Title
• Negative Sentiment: Ascendiant lowered its Q2 2026, Q3 2026, Q4 2026, and FY2026 EPS estimates, signaling weaker near-term earnings expectations and adding to investor concerns about the company’s path to profitability. Article Title

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.